Renji Hospital is a general hospital in the Pudong District of Shanghai, China, with the rank of "Grade 3, Class A". The hospital is a university hospital affiliated to the Shanghai Jiao Tong University School of Medicine.

There are 1,600 beds in Renji Hospital Affiliated to Shanghai Jiaotong University.

During the past decade, Renji Hospital Affiliated to Shanghai Jiaotong University conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Renji Hospital Affiliated to Shanghai Jiaotong University" #1 collaborator was "RenJi Hospital" with 2 trials as a collaborator, "Beijing Obstetrics and Gynecology Hospital" with 1 trials as a collaborator, "First Affiliated Hospital, Sun Yat-Sen University" with 1 trials as a collaborator, "Foshan Fuxing Changcheng Hospital" with 1 trials as a collaborator and "West China Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Renji Hospital Affiliated to Shanghai Jiaotong University" are "Acute-On-Chronic Liver Failure" (1 trials), "Antioxidative Stress" (1 trials), "Asymptomatic COVID-19" (1 trials), "COVID-19" (1 trials) and "Coronary Heart Disease" (1 trials). Many other conditions were trialed in "Renji Hospital Affiliated to Shanghai Jiaotong University" in a lesser frequency.

Most popular intervention types in "Renji Hospital Affiliated to Shanghai Jiaotong University" are "Drug" (3 trials), "Genetic" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cepharanthine" (1 trials), "Droperidol Injection" (1 trials), "Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)" (1 trials), "Korean red ginseng capsule (marketed product in Korea)" (1 trials) and "Korean red ginseng capsule(placebo)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Renji Hospital Affiliated to Shanghai Jiaotong University" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Renji Hospital Affiliated to Shanghai Jiaotong University". 1 are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Renji Hospital Affiliated to Shanghai Jiaotong University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Renji Hospital Affiliated to Shanghai Jiaotong University, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".